The Endometriosis Market size was valued at USD 1.35 Billion in 2023 and the total Endometriosis Market is expected to grow at a CAGR of 12.6% from 2024 to 2030, reaching nearly USD 3.10 Billion. The Endometriosis Market refers to the industry involved in the development, production, and distribution of products for the treatment of endometriosis. Endometriosis is a medical condition that occurs when tissue similar to the endometrium grows outside of the uterus, such as on the ovaries, fallopian tubes, and surrounding tissues in the pelvis and abdomen. It is categorized into four types based on the affected area: superficial peritoneal endometriosis, endometriomas, deeply infiltrating endometriosis, and abdominal wall endometriosis. Various treatments are available for endometriosis, including oral contraceptives, gonadotropin-releasing hormone (GnRH) medicines, aromatase inhibitors, and nonsteroidal anti-inflammatory drugs (NSAIDs). The Endometriosis Market is driven by increasing disease burden, rising disease awareness, and robust product pipeline. However, the industry also faces competition from generic and off-label products, which may impede its growth. In 2023, the global population of reproductive-age females with endometriosis was approximately 190 million, representing about 10% of the female population. Despite the high prevalence, healthcare workers report delays in diagnosis due to the broad and variable symptoms of endometriosis. This delay in diagnosis exacerbates symptoms, increasing the need for treatment and contributing to limited awareness of the condition.To know about the Research Methodology :- Request Free Sample Report
Competitive Landscapes:
The Endometriosis Market is moderately competitive, with leading companies holding a majority share of the market. However, the forecast period is expected to see an increase in new entrants, which could make the market increasingly competitive. Key players in the endometriosis treatment market are undertaking strategic initiatives such as new launches, collaborations, mergers, and acquisitions, which are further driving market growth. For Instance, in February 2022, Theramex and ObsEva SA announced a strategic licensing agreement to support the commercialization and expansion of Linzagolix across the global market. This strategic initiative is expected to strengthen the position of these key players in the market. The regulatory approvals for products are a significant contributor to competitive advantage for players in the Endometriosis Market. In August 2022, Myovant Sciences and Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) had approved Myfembree (relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg) for the once-daily treatment of moderate-to-severe endometriosis-associated pain. This approval is an important milestone reflecting Pfizer and Myovant's commitment to women's health in areas of significant unmet need.Similarly, in June 2022, Genes2Me Pvt. Ltd., a leading IVD solution manufacturer in India, launched CoviEasy, a self-test rapid antigen test kit for COVID-19 that delivers faster results in 10 minutes and is easy to use. Backed by an AI-driven mobile app, this IVD product provides a high level of sensitivity and concordance, with more than 98% accuracy. These product launches and advancements in technology by major players in the at-home testing market indicate the intensity of industry rivalry and the need for innovation to stay competitive. The market is expected to continue to witness high competition in the forecast period, as companies strive to capture a larger market share through new product launches, strategic partnerships, and mergers and acquisitions
Endometriosis Market Dynamics:
Increasing Public Awareness Initiatives are driving the Endometriosis Market growth during the forecast period Endometriosis awareness programs occur annually across various countries globally to raise awareness about the disease. These initiatives include conferences and virtual forums where experts discuss the myths and facts associated with endometriosis. For example, on March 12th, Austria hosted a free full-day online congress that provided knowledge from experts on endometriosis. Similarly, on March 19th and 20th, 2022, the Endometriosis and Reproductive Health Foundation in Bulgaria organized a virtual conference called "Myths and Truths About the Disease" to discuss common myths associated with the disease. Other countries, including Canada, Bangladesh, Finland, France, Hungary, and India, have also raised a series of activities to encourage open discussion about endometriosis. Such initiatives are expected to drive the endometriosis treatment market during the forecast period, as they increase public awareness and understanding of the disease. The government and key market players are also actively investing in research and development and increasing funds to further cater to market growth. For example, in March 2022, the U.S. federal government announced USD 92 million funds to the National Institute of Child Health and Human Development (NICHD) for endometriosis research. Similarly, in February 2021, DBT Wellcome India Alliance announced a grant of USD 0.47 million for the Endometriosis Clinical and Genetic Research in India (ECGRI) project, which aims to conduct an endometriosis clinical study on genetic risks and phenotypes associated with the disease Continuous R&D for Advanced Drug Technology Driving Growth in the Endometriosis Market The Endometriosis Therapeutics Market is expected to experience significant growth due to the evolution of methods and drugs as a result of technological advancement. Market players are proposing novel drug delivery technologies, such as topical applicators, to overcome the side effects of oral contraceptives and improve efficiency, as many women sufferings from endometriosis increase the demand for treatment. . The industry is responding to market requirements by proposing novel drug delivery technologies to improve treatment efficiency and reduce side effects. The introduction of new products with improved pharmacological profiles and delivery systems is driving the growth of the industry. For instance, in 2022, Astellas Pharma Inc. announced the outcome of the clinical trial version Phase 3 for their non-hormonal composite, "SKYLIGHT 4", which is being studied for treating sensible to severe vasomotor symptoms associated with menopause (VMS). This advancement will encourage future regulatory organizing submissions. In the Endometriosis industry, research and development are essential components of growth and competitiveness. Continuous investment in research and development by key market players is driving the development of advanced drug technology for the treatment of endometriosis. This has enabled the introduction of new products with higher efficiency, improved safety profiles, and fewer side effects. As a result, there is an increased focus on research and development of drugs with improved pharmacological profiles and delivery systems.Endometriosis Market Segment Analysis:
Based on treatment type, the endometriosis market is segmented into Pain Medication Hormone Therapy. According to the segment analysis of the Endometriosis Market, the pain medication segment accounted for a highest Market Share in 2023. This segment is driven by the need to alleviate the painful symptoms experienced by endometriosis patients, including dysmenorrhea, dyspareunia, chronic pelvic pain, infertility, and psychological distress. Medications that can effectively suppress these painful symptoms have fewer side effects, reasonable costs, good tolerance, and high safety profiles, leading to an increase in their demand. NSAIDs, such as ibuprofen, paracetamol, and naproxen, are the most commonly prescribed pain medications for endometriosis patients.On the other hand, the hormone therapy segment is expected to witness a CAGR of 13.99% during the forecast period. Hormone therapy includes prominent therapeutic products such as the Relugolix combination tablet from Myovant/Pfizer and Yselty (linzagolix) from ObsEva, which are expected to drive the growth of this segment. Strategic collaborations between key players in the market are also expected to boost market growth. For example, in February 2023, ObsEva SA and Theramex entered into a strategic licensing agreement to expand the use of linzagolix outside of the U.S., Canada, and Asia. Linzagolix has shown potential as a treatment for endometriosis-associated pain. By Drug Class, the endometriosis market is segmented into NSAIDs, Oral Contraceptive, Gonadotropin Releasing Hormone and Others. In 2023, the NSAIDs segment accounted for a significant share of 19.50% in the Endometriosis market. The immediate pain relief effects and their availability as both over-the-counter and prescription drugs at a reasonable cost with NSAIDS is driving the segment growth. Nonsteroidal anti-inflammatory drugs such as paracetamol, ibuprofen and naproxen work by blocking the production of prostaglandins and are effective in reducing mild to moderate pain. Over the forecast period, the Gonadotropin-releasing hormone (GnRH) medicines segment is expected to dominate the Endometriosis market. Available in various forms such as pills, shots, injections, or nasal sprays, these medicines are prescribed to treat pain associated with the disease. AbbVie Inc.’s Orilissa (elagolix) was the first pill approved by the FDA for this purpose. GnRH agonists and antagonists such as Zoladex, Lupron, Orilissa and Synarel are used as an alternative treatment for patients who are resistant to first-line treatment. One major advantage of this treatment is that after completion, patients return to a normal menstrual cycle and their ability to conceive is not affected. Based on route of administration, the endometriosis market is segmented into Oral, Injectable & others. In 2023, the oral route of administration was the dominant segment in the Endometriosis Market, accounting for a revenue share of 19.7%. This segment is expected to maintain its share over the forecast period due to its common and convenient route of administration for painkillers, good bioavailability, and effectiveness for hormone therapy. The oral route of administration includes NSAIDs, oral contraceptives, oral progestins such as Aygestin and Provera, and oral GnRH agonists, which are driving the segment growth. The introduction of AbbVie's Orilissa (elagolix), the first orally administered GnRH antagonist for the management of endometriosis, is fueling the segment. On the other hand, the other route of administration is expected to witness a CAGR of 5.35% during the forecast period. This growth can be attributed to the presence of topical formulations as novel transdermal drug delivery technologies, which demonstrate increased efficacy by bypassing first-pass metabolism. The segment includes contraceptive patches such as Twirla and Xulane. Furthermore, key players are showing interest in developing such a transdermal system, which is boosting the segment growth. For example, Noven Pharmaceuticals has developed CombiPatch, which is a combination patch (estradiol/norethindrone acetate) for the treatment of endometriosis. By Distribution Channel, the endometriosis market is segregated into retail pharmacies, hospital pharmacies and others. The distribution channel segment analysis of the Endometriosis Market reveals that the retail pharmacy segment held the largest revenue share of 67.4% in 2023. This can be attributed to the fact that most endometriosis patients receive treatment in outpatient settings and over-the-counter drugs are readily available at retail pharmacies. Moreover, factors such as the rising volume of prescriptions for endometriosis drugs, growing awareness of the disease, and increasing healthcare expenditure are driving the Endometriosis market growth in this segment.
On the other hand, the hospital pharmacy segment is expected to experience moderate growth during the forecast period. The rising preference for surgery as an endometriosis treatment option in a hospital setting is a major driver for this segment. Additionally, hospital pharmacists, as medication experts, can assist patients with endometriosis and their caregivers in selecting appropriate medications, thereby supporting segment growth.
Endometriosis Market Regional Insights:
The global endometriosis market is studied across various regions, including North America, Europe, Asia-Pacific, and LAMEA. North America holds the largest market share and is expected to maintain its dominance during the forecast period. This is due to the presence of major players such as Abbott Laboratories, Merck & Co. Inc., and Pfizer Inc., as well as advancements in manufacturing technology for medicines. The surge in incidences of endometriosis that require treatment with gonadotropin-releasing hormone (GnRH) medicines, along with funding from governments for research regarding endometriosis treatment, and a significant rise in capital income in developed countries, also contribute to the growth of the market. The sophisticated reimbursement structure in North America, aimed at reducing expenditure levels, is another factor that drives market growth. The United States is anticipated to contribute to a major share of the regional market and is expected to drive the growth of the endometriosis market throughout the forecast period. The presence of a well-established healthcare infrastructure, high purchasing power, and a rise in the adoption rate of endometriosis medicine are expected to drive market growth in the US. On the other hand, the Asia-Pacific region is expected to experience the highest growth rate during the endometriosis market forecast period. This growth is attributed to the increase in the number of endometriosis cases in the region, as well as the growth in purchasing power of highly populated countries, such as China and India. These countries have a huge population base, with China being the most populated country in the world with 1,397,715 population in 2023 and India being the second most populated country with 1,366,417.75 population in 2023. As a result, this presents significant growth opportunities for the endometriosis market in the Asia-Pacific region.Endometriosis Market Scope: Inquire before buying
Endometriosis Market Report Coverage Details Base Year: 2023 Forecast Period: 2024-2030 Historical Data: 2018 to 2023 Market Size in 2023: US $ 1.35 Bn. Forecast Period 2024 to 2030 CAGR: 12.6% Market Size in 2030: US $ 3.10 Bn. Segments Covered: by Treatment Type 1. Pain Management 2. Home Therapy by Drug Class 1. NSAID’s 2.Oral Contraceptives 3.Gonadotropin Releasing Hormone 4.Others by Route of Administration 1. Oral 2. Injectable 3.Others by Distribution Channel 1.Retail Pharmacies 2. Hospital Pharmacies 3. Others Endometriosis Market, by Region
North America (United States, Canada and Mexico) Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe) Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC) Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A) South America (Brazil, Argentina Rest of South America)Endometriosis Market Key Players:
1. Bayer AG 2. Pfizer, Inc. 3. AbbVie, Inc 4. AstraZeneca; 5. ObsEva SA; 6. Teva Pharmaceutical Industries 7. Zydus Healthcare Limited; 8. Eli Lilly and Company 9. Astellas Pharma Inc 10. Consilient Health Limited, 11. Serum Institute of India Pvt. Ltd. 12. Abbott Laboratories 13. GlaxoSmithKline plc, 14. Merck & Co. Inc., 15. Sanofi 16. Sun Pharmaceutical Industries Ltd 17. Torrent Pharmaceuticals Ltd 18. Lanett 19. TerSera Therapeutics USA 20. Tolmar Pharmaceuticals, Inc FAQs: 1] What segments are covered in the Global Endometriosis Market report? Ans. The segments covered in the Endometriosis report are based on Treatment type, Drug Class, Route of Administration Distribution Channel and region. 2] Which region is expected to hold the highest share in the Global Endometriosis Market during the forecast period? Ans. The North America region is expected to hold the highest share of the Endometriosis market during the forecast period. 3] What is the market size of the Global Endometriosis by 2030? Ans. The market size of the Endometriosis by 2030 is expected to reach US$ 3.10 Bn. 4] What is the forecast period for the Global Endometriosis Market? Ans. The forecast period for the Endometriosis market is 2024-2030 5] What was the market size of the Global Endometriosis in 2023? Ans. The market size of the Endometriosis in 2023 was valued at US$ 1.35 Bn.
1. Endometriosis Market Introduction 1.1. Study Assumption and Market Definition 1.2. Scope of the Study 1.3. Executive Summary 2. Endometriosis Market: Dynamics 2.1. Endometriosis Market Trends by Region 2.1.1. North America Endometriosis Market Trends 2.1.2. Europe Endometriosis Market Trends 2.1.3. Asia Pacific Endometriosis Market Trends 2.1.4. Middle East and Africa Endometriosis Market Trends 2.1.5. South America Endometriosis Market Trends 2.2. Endometriosis Market Dynamics by Region 2.2.1. North America 2.2.1.1. North America Endometriosis Market Drivers 2.2.1.2. North America Endometriosis Market Restraints 2.2.1.3. North America Endometriosis Market Opportunities 2.2.1.4. North America Endometriosis Market Challenges 2.2.2. Europe 2.2.2.1. Europe Endometriosis Market Drivers 2.2.2.2. Europe Endometriosis Market Restraints 2.2.2.3. Europe Endometriosis Market Opportunities 2.2.2.4. Europe Endometriosis Market Challenges 2.2.3. Asia Pacific 2.2.3.1. Asia Pacific Endometriosis Market Drivers 2.2.3.2. Asia Pacific Endometriosis Market Restraints 2.2.3.3. Asia Pacific Endometriosis Market Opportunities 2.2.3.4. Asia Pacific Endometriosis Market Challenges 2.2.4. Middle East and Africa 2.2.4.1. Middle East and Africa Endometriosis Market Drivers 2.2.4.2. Middle East and Africa Endometriosis Market Restraints 2.2.4.3. Middle East and Africa Endometriosis Market Opportunities 2.2.4.4. Middle East and Africa Endometriosis Market Challenges 2.2.5. South America 2.2.5.1. South America Endometriosis Market Drivers 2.2.5.2. South America Endometriosis Market Restraints 2.2.5.3. South America Endometriosis Market Opportunities 2.2.5.4. South America Endometriosis Market Challenges 2.3. PORTER’s Five Forces Analysis 2.4. PESTLE Analysis 2.5. Technology Roadmap 2.6. Regulatory Landscape by Region 2.6.1. North America 2.6.2. Europe 2.6.3. Asia Pacific 2.6.4. Middle East and Africa 2.6.5. South America 2.7. Key Opinion Leader Analysis For Endometriosis Industry 2.8. Analysis of Government Schemes and Initiatives For Endometriosis Industry 2.9. Endometriosis Market Trade Analysis 2.10. The Global Pandemic Impact on Endometriosis Market 3. Endometriosis Market: Global Market Size and Forecast by Segmentation by Demand and Supply Side (by Value in USD Million) 2023-2030 3.1. Endometriosis Market Size and Forecast, by Treatment Type (2023-2030) 3.1.1. Pain Management 3.1.2. Home Therapy 3.2. Endometriosis Market Size and Forecast, by Drug Class (2023-2030) 3.2.1. NSAID’s 3.2.2. Oral Contraceptives 3.2.3. Gonadotropin Releasing Hormone 3.2.4. Others 3.3. Endometriosis Market Size and Forecast, by Route of Administration (2023-2030) 3.3.1. Oral 3.3.2. Injectable 3.3.3. Others 3.4. Endometriosis Market Size and Forecast, by Distribution Channel (2023-2030) 3.4.1. Retail Pharmacies 3.4.2. Hospital Pharmacies 3.4.3. Others 3.5. Endometriosis Market Size and Forecast, by Region (2023-2030) 3.5.1. North America 3.5.2. Europe 3.5.3. Asia Pacific 3.5.4. Middle East and Africa 3.5.5. South America 4. North America Endometriosis Market Size and Forecast by Segmentation (by Value in USD Million) 2023-2030 4.1. North America Endometriosis Market Size and Forecast, by Treatment Type (2023-2030) 4.1.1. Pain Management 4.1.2. Home Therapy 4.2. North America Endometriosis Market Size and Forecast, by Drug Class (2023-2030) 4.2.1. NSAID’s 4.2.2. Oral Contraceptives 4.2.3. Gonadotropin Releasing Hormone 4.2.4. Others 4.3. North America Endometriosis Market Size and Forecast, by Route of Administration (2023-2030) 4.3.1. Oral 4.3.2. Injectable 4.3.3. Others 4.4. North America Endometriosis Market Size and Forecast, by Distribution Channel (2023-2030) 4.4.1. Retail Pharmacies 4.4.2. Hospital Pharmacies 4.4.3. Others 4.5. North America Endometriosis Market Size and Forecast, by Country (2023-2030) 4.5.1. United States 4.5.1.1. United States Endometriosis Market Size and Forecast, by Treatment Type (2023-2030) 4.5.1.1.1. Pain Management 4.5.1.1.2. Home Therapy 4.5.1.2. United States Endometriosis Market Size and Forecast, by Drug Class (2023-2030) 4.5.1.2.1. NSAID’s 4.5.1.2.2. Oral Contraceptives 4.5.1.2.3. Gonadotropin Releasing Hormone 4.5.1.2.4. Others 4.5.1.3. United States Endometriosis Market Size and Forecast, by Route of Administration (2023-2030) 4.5.1.3.1. Oral 4.5.1.3.2. Injectable 4.5.1.3.3. Others 4.5.1.4. United States Endometriosis Market Size and Forecast, by Distribution Channel (2023-2030) 4.5.1.4.1. Retail Pharmacies 4.5.1.4.2. Hospital Pharmacies 4.5.1.4.3. Others 4.5.2. Canada 4.5.2.1. Canada Endometriosis Market Size and Forecast, by Treatment Type (2023-2030) 4.5.2.1.1. Pain Management 4.5.2.1.2. Home Therapy 4.5.2.2. Canada Endometriosis Market Size and Forecast, by Drug Class (2023-2030) 4.5.2.2.1. NSAID’s 4.5.2.2.2. Oral Contraceptives 4.5.2.2.3. Gonadotropin Releasing Hormone 4.5.2.2.4. Others 4.5.2.3. Canada Endometriosis Market Size and Forecast, by Route of Administration (2023-2030) 4.5.2.3.1. Oral 4.5.2.3.2. Injectable 4.5.2.3.3. Others 4.5.2.4. Canada Endometriosis Market Size and Forecast, by Distribution Channel (2023-2030) 4.5.2.4.1. Retail Pharmacies 4.5.2.4.2. Hospital Pharmacies 4.5.2.4.3. Others 4.5.3. Mexico 4.5.3.1. Mexico Endometriosis Market Size and Forecast, by Treatment Type (2023-2030) 4.5.3.1.1. Pain Management 4.5.3.1.2. Home Therapy 4.5.3.2. Mexico Endometriosis Market Size and Forecast, by Drug Class (2023-2030) 4.5.3.2.1. NSAID’s 4.5.3.2.2. Oral Contraceptives 4.5.3.2.3. Gonadotropin Releasing Hormone 4.5.3.2.4. Others 4.5.3.3. Mexico Endometriosis Market Size and Forecast, by Route of Administration (2023-2030) 4.5.3.3.1. Oral 4.5.3.3.2. Injectable 4.5.3.3.3. Others 4.5.3.4. Mexico Endometriosis Market Size and Forecast, by Distribution Channel (2023-2030) 4.5.3.4.1. Retail Pharmacies 4.5.3.4.2. Hospital Pharmacies 4.5.3.4.3. Others 5. Europe Endometriosis Market Size and Forecast by Segmentation (by Value in USD Million) 2023-2030 5.1. Europe Endometriosis Market Size and Forecast, by Treatment Type (2023-2030) 5.1. Europe Endometriosis Market Size and Forecast, by Drug Class (2023-2030) 5.1. Europe Endometriosis Market Size and Forecast, by Route of Administration (2023-2030) 5.1. Europe Endometriosis Market Size and Forecast, by Distribution Channel (2023-2030) 5.5. Europe Endometriosis Market Size and Forecast, by Country (2023-2030) 5.5.1. United Kingdom 5.5.1.1. United Kingdom Endometriosis Market Size and Forecast, by Treatment Type (2023-2030) 5.5.1.2. United Kingdom Endometriosis Market Size and Forecast, by Drug Class (2023-2030) 5.5.1.3. United Kingdom Endometriosis Market Size and Forecast, by Route of Administration (2023-2030) 5.5.1.4. United Kingdom Endometriosis Market Size and Forecast, by Distribution Channel (2023-2030) 5.5.2. France 5.5.2.1. France Endometriosis Market Size and Forecast, by Treatment Type (2023-2030) 5.5.2.2. France Endometriosis Market Size and Forecast, by Drug Class (2023-2030) 5.5.2.3. France Endometriosis Market Size and Forecast, by Route of Administration (2023-2030) 5.5.2.4. France Endometriosis Market Size and Forecast, by Distribution Channel (2023-2030) 5.5.3. Germany 5.5.3.1. Germany Endometriosis Market Size and Forecast, by Treatment Type (2023-2030) 5.5.3.2. Germany Endometriosis Market Size and Forecast, by Drug Class (2023-2030) 5.5.3.3. Germany Endometriosis Market Size and Forecast, by Route of Administration (2023-2030) 5.5.3.4. Germany Endometriosis Market Size and Forecast, by Distribution Channel (2023-2030) 5.5.4. Italy 5.5.4.1. Italy Endometriosis Market Size and Forecast, by Treatment Type (2023-2030) 5.5.4.2. Italy Endometriosis Market Size and Forecast, by Drug Class (2023-2030) 5.5.4.3. Italy Endometriosis Market Size and Forecast, by Route of Administration (2023-2030) 5.5.4.4. Italy Endometriosis Market Size and Forecast, by Distribution Channel (2023-2030) 5.5.5. Spain 5.5.5.1. Spain Endometriosis Market Size and Forecast, by Treatment Type (2023-2030) 5.5.5.2. Spain Endometriosis Market Size and Forecast, by Drug Class (2023-2030) 5.5.5.3. Spain Endometriosis Market Size and Forecast, by Route of Administration (2023-2030) 5.5.5.4. Spain Endometriosis Market Size and Forecast, by Distribution Channel (2023-2030) 5.5.6. Sweden 5.5.6.1. Sweden Endometriosis Market Size and Forecast, by Treatment Type (2023-2030) 5.5.6.2. Sweden Endometriosis Market Size and Forecast, by Drug Class (2023-2030) 5.5.6.3. Sweden Endometriosis Market Size and Forecast, by Route of Administration (2023-2030) 5.5.6.4. Sweden Endometriosis Market Size and Forecast, by Distribution Channel (2023-2030) 5.5.7. Austria 5.5.7.1. Austria Endometriosis Market Size and Forecast, by Treatment Type (2023-2030) 5.5.7.2. Austria Endometriosis Market Size and Forecast, by Drug Class (2023-2030) 5.5.7.3. Austria Endometriosis Market Size and Forecast, by Route of Administration (2023-2030) 5.5.7.4. Austria Endometriosis Market Size and Forecast, by Distribution Channel (2023-2030) 5.5.8. Rest of Europe 5.5.8.1. Rest of Europe Endometriosis Market Size and Forecast, by Treatment Type (2023-2030) 5.5.8.2. Rest of Europe Endometriosis Market Size and Forecast, by Drug Class (2023-2030) 5.5.8.3. Rest of Europe Endometriosis Market Size and Forecast, by Route of Administration (2023-2030) 5.5.8.4. Rest of Europe Endometriosis Market Size and Forecast, by Distribution Channel (2023-2030) 6. Asia Pacific Endometriosis Market Size and Forecast by Segmentation (by Value in USD Million) 2023-2030 6.1. Asia Pacific Endometriosis Market Size and Forecast, by Treatment Type (2023-2030) 6.2. Asia Pacific Endometriosis Market Size and Forecast, by Drug Class (2023-2030) 6.3. Asia Pacific Endometriosis Market Size and Forecast, by Route of Administration (2023-2030) 6.4. Asia Pacific Endometriosis Market Size and Forecast, by Distribution Channel (2023-2030) 6.5. Asia Pacific Endometriosis Market Size and Forecast, by Country (2023-2030) 6.5.1. China 6.5.1.1. China Endometriosis Market Size and Forecast, by Treatment Type (2023-2030) 6.5.1.2. China Endometriosis Market Size and Forecast, by Drug Class (2023-2030) 6.5.1.3. China Endometriosis Market Size and Forecast, by Route of Administration (2023-2030) 6.5.1.4. China Endometriosis Market Size and Forecast, by Distribution Channel (2023-2030) 6.5.2. S Korea 6.5.2.1. S Korea Endometriosis Market Size and Forecast, by Treatment Type (2023-2030) 6.5.2.2. S Korea Endometriosis Market Size and Forecast, by Drug Class (2023-2030) 6.5.2.3. S Korea Endometriosis Market Size and Forecast, by Route of Administration (2023-2030) 6.5.2.4. S Korea Endometriosis Market Size and Forecast, by Distribution Channel (2023-2030) 6.5.3. Japan 6.5.3.1. Japan Endometriosis Market Size and Forecast, by Treatment Type (2023-2030) 6.5.3.2. Japan Endometriosis Market Size and Forecast, by Drug Class (2023-2030) 6.5.3.3. Japan Endometriosis Market Size and Forecast, by Route of Administration (2023-2030) 6.5.3.4. Japan Endometriosis Market Size and Forecast, by Distribution Channel (2023-2030) 6.5.4. India 6.5.4.1. India Endometriosis Market Size and Forecast, by Treatment Type (2023-2030) 6.5.4.2. India Endometriosis Market Size and Forecast, by Drug Class (2023-2030) 6.5.4.3. India Endometriosis Market Size and Forecast, by Route of Administration (2023-2030) 6.5.4.4. India Endometriosis Market Size and Forecast, by Distribution Channel (2023-2030) 6.5.5. Australia 6.5.5.1. Australia Endometriosis Market Size and Forecast, by Treatment Type (2023-2030) 6.5.5.2. Australia Endometriosis Market Size and Forecast, by Drug Class (2023-2030) 6.5.5.3. Australia Endometriosis Market Size and Forecast, by Route of Administration (2023-2030) 6.5.5.4. Australia Endometriosis Market Size and Forecast, by Distribution Channel (2023-2030) 6.5.6. Indonesia 6.5.6.1. Indonesia Endometriosis Market Size and Forecast, by Treatment Type (2023-2030) 6.5.6.2. Indonesia Endometriosis Market Size and Forecast, by Drug Class (2023-2030) 6.5.6.3. Indonesia Endometriosis Market Size and Forecast, by Route of Administration (2023-2030) 6.5.6.4. Indonesia Endometriosis Market Size and Forecast, by Distribution Channel (2023-2030) 6.5.7. Malaysia 6.5.7.1. Malaysia Endometriosis Market Size and Forecast, by Treatment Type (2023-2030) 6.5.7.2. Malaysia Endometriosis Market Size and Forecast, by Drug Class (2023-2030) 6.5.7.3. Malaysia Endometriosis Market Size and Forecast, by Route of Administration (2023-2030) 6.5.7.4. Malaysia Endometriosis Market Size and Forecast, by Distribution Channel (2023-2030) 6.5.8. Vietnam 6.5.8.1. Vietnam Endometriosis Market Size and Forecast, by Treatment Type (2023-2030) 6.5.8.2. Vietnam Endometriosis Market Size and Forecast, by Drug Class (2023-2030) 6.5.8.3. Vietnam Endometriosis Market Size and Forecast, by Route of Administration (2023-2030) 6.5.8.4. Vietnam Endometriosis Market Size and Forecast, by Distribution Channel (2023-2030) 6.5.9. Taiwan 6.5.9.1. Taiwan Endometriosis Market Size and Forecast, by Treatment Type (2023-2030) 6.5.9.2. Taiwan Endometriosis Market Size and Forecast, by Drug Class (2023-2030) 6.5.9.3. Taiwan Endometriosis Market Size and Forecast, by Route of Administration (2023-2030) 6.5.9.4. Taiwan Endometriosis Market Size and Forecast, by Distribution Channel (2023-2030) 6.5.10. Rest of Asia Pacific 6.5.10.1. Rest of Asia Pacific Endometriosis Market Size and Forecast, by Treatment Type (2023-2030) 6.5.10.2. Rest of Asia Pacific Endometriosis Market Size and Forecast, by Drug Class (2023-2030) 6.5.10.3. Rest of Asia Pacific Endometriosis Market Size and Forecast, by Route of Administration (2023-2030) 6.5.10.4. Rest of Asia Pacific Endometriosis Market Size and Forecast, by Distribution Channel (2023-2030) 7. Middle East and Africa Endometriosis Market Size and Forecast by Segmentation (by Value in USD Million) 2023-2030 7.1. Middle East and Africa Endometriosis Market Size and Forecast, by Treatment Type (2023-2030) 7.2. Middle East and Africa Endometriosis Market Size and Forecast, by Drug Class (2023-2030) 7.3. Middle East and Africa Endometriosis Market Size and Forecast, by Route of Administration (2023-2030) 7.4. Middle East and Africa Endometriosis Market Size and Forecast, by Distribution Channel (2023-2030) 7.5. Middle East and Africa Endometriosis Market Size and Forecast, by Country (2023-2030) 7.5.1. South Africa 7.5.1.1. South Africa Endometriosis Market Size and Forecast, by Treatment Type (2023-2030) 7.5.1.2. South Africa Endometriosis Market Size and Forecast, by Drug Class (2023-2030) 7.5.1.3. South Africa Endometriosis Market Size and Forecast, by Route of Administration (2023-2030) 7.5.1.4. South Africa Endometriosis Market Size and Forecast, by Distribution Channel (2023-2030) 7.5.2. GCC 7.5.2.1. GCC Endometriosis Market Size and Forecast, by Treatment Type (2023-2030) 7.5.2.2. GCC Endometriosis Market Size and Forecast, by Drug Class (2023-2030) 7.5.2.3. GCC Endometriosis Market Size and Forecast, by Route of Administration (2023-2030) 7.5.2.4. GCC Endometriosis Market Size and Forecast, by Distribution Channel (2023-2030) 7.5.3. Nigeria 7.5.3.1. Nigeria Endometriosis Market Size and Forecast, by Treatment Type (2023-2030) 7.5.3.2. Nigeria Endometriosis Market Size and Forecast, by Drug Class (2023-2030) 7.5.3.3. Nigeria Endometriosis Market Size and Forecast, by Route of Administration (2023-2030) 7.5.3.4. Nigeria Endometriosis Market Size and Forecast, by Distribution Channel (2023-2030) 7.5.4. Rest of ME&A 7.5.4.1. Rest of ME&A Endometriosis Market Size and Forecast, by Treatment Type (2023-2030) 7.5.4.2. Rest of ME&A Endometriosis Market Size and Forecast, by Drug Class (2023-2030) 7.5.4.3. Rest of ME&A Endometriosis Market Size and Forecast, by Route of Administration (2023-2030) 7.5.4.4. Rest of ME&A Endometriosis Market Size and Forecast, by Distribution Channel (2023-2030) 8. South America Endometriosis Market Size and Forecast by Segmentation (by Value in USD Million) 2023-2030 8.1. South America Endometriosis Market Size and Forecast, by Treatment Type (2023-2030) 8.2. South America Endometriosis Market Size and Forecast, by Drug Class (2023-2030) 8.3. South America Endometriosis Market Size and Forecast, by Route of Administration(2023-2030) 8.4. South America Endometriosis Market Size and Forecast, by Distribution Channel (2023-2030) 8.5. South America Endometriosis Market Size and Forecast, by Country (2023-2030) 8.5.1. Brazil 8.5.1.1. Brazil Endometriosis Market Size and Forecast, by Treatment Type (2023-2030) 8.5.1.2. Brazil Endometriosis Market Size and Forecast, by Drug Class (2023-2030) 8.5.1.3. Brazil Endometriosis Market Size and Forecast, by Route of Administration (2023-2030) 8.5.1.4. Brazil Endometriosis Market Size and Forecast, by Distribution Channel (2023-2030) 8.5.2. Argentina 8.5.2.1. Argentina Endometriosis Market Size and Forecast, by Treatment Type (2023-2030) 8.5.2.2. Argentina Endometriosis Market Size and Forecast, by Drug Class (2023-2030) 8.5.2.3. Argentina Endometriosis Market Size and Forecast, by Route of Administration (2023-2030) 8.5.2.4. Argentina Endometriosis Market Size and Forecast, by Distribution Channel (2023-2030) 8.5.3. Rest Of South America 8.5.3.1. Rest Of South America Endometriosis Market Size and Forecast, by Treatment Type (2023-2030) 8.5.3.2. Rest Of South America Endometriosis Market Size and Forecast, by Drug Class (2023-2030) 8.5.3.3. Rest Of South America Endometriosis Market Size and Forecast, by Route of Administration (2023-2030) 8.5.3.4. Rest Of South America Endometriosis Market Size and Forecast, by Distribution Channel (2023-2030) 9. Global Endometriosis Market: Competitive Landscape 9.1. MMR Competition Matrix 9.2. Competitive Landscape 9.3. Key Players Benchmarking 9.3.1. Company Name 9.3.2. Business Segment 9.3.3. End-user Segment 9.3.4. Revenue (2023) 9.3.5. Company Locations 9.4. Leading Endometriosis Market Companies, by market capitalization 9.5. Market Structure 9.5.1. Market Leaders 9.5.2. Market Followers 9.5.3. Emerging Players 9.6. Mergers and Acquisitions Details 10. Company Profile: Key Players 10.1. Bayer AG 10.1.1. Company Overview 10.1.2. Business Portfolio 10.1.3. Financial Overview 10.1.4. SWOT Analysis 10.1.5. Strategic Analysis 10.1.6. Scale of Operation (small, medium, and large) 10.1.7. Details on Partnership 10.1.8. Regulatory Accreditations and Certifications Received by Them 10.1.9. Awards Received by the Firm 10.1.10. Recent Developments 10.2. Pfizer, Inc. 10.3. AbbVie, Inc 10.4. AstraZeneca; 10.5. ObsEva SA; 10.6. Teva Pharmaceutical Industries 10.7. Zydus Healthcare Limited; 10.8. Eli Lilly and Company 10.9. Astellas Pharma Inc 10.10. Consilient Health Limited, 10.11. Serum Institute of India Pvt. Ltd. 10.12. Abbott Laboratories 10.13. GlaxoSmithKline plc, 10.14. Merck & Co. Inc., 10.15. Sanofi 10.16. Sun Pharmaceutical Industries Ltd 10.17. Torrent Pharmaceuticals Ltd 10.18. Lanett 10.19. TerSera Therapeutics USA 10.20. Tolmar Pharmaceuticals, Inc 11. Key Findings 12. Industry Recommendations 13. Endometriosis Market: Research Methodology 14. Terms and Glossary